Renal osteodystrophy

Current Opinion in Pediatrics

Volumn 10, Issue 2, 1998, Pages 190-196

  Dabbagh, Shermine ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM ION; CYTOKINE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D;

ALBRIGHT SYNDROME; BONE MALFORMATION; CALCIUM BALANCE; CALCIUM METABOLISM; CHRONIC KIDNEY FAILURE; GROWTH DISORDER; HUMAN; METABOLIC ACIDOSIS; PHOSPHATE BALANCE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; URINE RETENTION; VITAMIN INTAKE;

ACIDOSIS; CHILD; CYTOKINES; HUMANS; HYPERPARATHYROIDISM; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY;

EID: 0031804661     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199804000-00013     Document Type: Review

References (82)

1. Lucas RC: On a form of late rickets associated with albuminuria, rickets of adolescence. Lancet 1883, 1:993-1000.
2. Liu SH, Chu E: Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (AT 10) and iron. Medicine 1943, 22:103-161.
3. Stanbury SW: Azotemic renal osteodystrophy. Br Med Bull 1957, 13:57-60.
4. Arnaud CD: Hyperparathyroidism and renal failure. Kidney Int 1973, 4:89-95.
5. Slatopolsky E, Caglar S, Pennell JP, et al.: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971, 50:492-499.
6. Slatopolsky E, Caglar S, Gradowska L, et al.: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 1972, 2:147-151.
7. Llach F, Massry SG, Koffler A, et al.: Secondary hyperparathyroidism in early renal failure: Role of phosphate retention. Kidney Int 1977, 12:459-463.
8. Fortino S: Phosphate excretion in chronic renal failure: evidence for a mechanism other than ciculating parathyroid hormone. Clin Nephrol 1977, 8:499-503.
9. Fournier AE, Arnaud CD, Johnson WJ, et al.: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 1971, 50:599-605.
10. Portale AA, Booth BE, Halloran BP, et al.: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984, 73:1580-1589.
11. Lopez-Hilker S, Galceran T, Chan Y, et al.: Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1987, 78:1097-1102.
12. Lopez-Hilker S, Dusso As, Rapp NS, et al.: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990, 259:F432-F437.
13. Tanaka Y, DeLuca HF: The control of 25-hydroxyvltamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 1973, 159:566-571.
14. Llach F, Massry SG: On the mechanism of the prevention of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985, 61:601-606.
15. 2D. Kidney Int 1985, 27:565-573.
16. 3 response to low calcium diet. Am J Physiol 1982, 243:F570-F575.
17. Llach F, Massry SG, Singer FR, et al.: Skeletal resistance of endogenous parathyroid hormone in patients with early renal failure: A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 1975, 41:339-345.
18. 3. Kidney Int 1976, 9:467-474.
19. Olgaard K, Schwartz J, Finco D, et al.: Extraction of parathyroid hormone and release of cyclic-AMP by isolated perfused bones obtained from dogs with acute uremia. Endocrinology 1982, 111:1678-1682.
20. Olgaard K, Arbelaez M, Schwartz J, et al.: Abnormal skeletal response to parathyroid hormone in dogs with chronic uremia. Skeletal cyclic-AMP response to PTH in chronic uremia. Calcif Tissue Int 1982, 34:403-407.
21. Galcer E: Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney Int 1987, 32:801-807.
22. Brown EM: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983, 56:572-581.
23. Delmez JA, Tindira C, Grooms P, et al.: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989, 83:1349-1355.
24. Ramirez JA, Goodman WG, Belin T, et al.: Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol 1994, 267:E961-E967.
25. Goodman WG, Belin TR, Salusky IB: In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. Kidney Int 1996, 50:1834-1844.
26. 3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987, 316:1573-1577.
27. Kremer R, Bolivar I, Goltzman D, et al.: Influence of calcium and 1.25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989, 125:935-941.
28. Indridason OS, Heath H, Khosla S, et al.: Non-suppressible parathyroid hormone secretion is related to gland size in uremic hyperparathyroidism. Kidney Int 1996, 50:1663-1671.
29. Lemann J Jr, Litzow JR, Lennon EJ: The effects of chronic acid loads in normal man: Further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest 1966, 45:1608-1614.
30. Bushinsky DA, Ori Y: Effects of metabolic and respiratory acidosis on bone. Curr Opin Nephrol Hypertens 1993, 2:588-596.
31. Bushinsky DA, Lechleider RJ: Mechanism of proton-induced calcium release: calcium carbonate dissolution. Am J Physiol 1987, 253:F998-F1005.
32. Bushinsky DA, Levi-Setti R, Coe FL: Ion microprobe determination of bone surface elements. Effects of reduced medium pH. Am J Physiol 1986, 250:F1090-F1097.
33. Krieger NS, Sessler NE, Bushinsky DA: Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol 1992, 262:F442-F448.
34. Lefebvre A, De Vernejoul DC, Gueris J, et al.: Optimal correction of acidosis changes progression of renal osteodystrophy. Kidney Int 1989, 36:1112-1118.
35. Weber HP, Gray RW, Dominguez JH, et al.: The lack of effect of chronic metabolic acidosis on 25-OH vitamin D metabolism and serum parathyroid hormone in humans. J Clin Endocrinol Metab 1976, 43:1047-1055.
36. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995, 333:166-174.
37. Monier-Faugere M-C, Malluche HH: Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997, 6:327-332.
38. Descamps-Latscha B, Herbelin A, Nguyen AT, et al.: Balance between IL-1β, TNFα1 and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 1995, 154:882-892.
39. Brockhaus M, Bar-Khayim Y, Gurwicz S, et al: Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1991, 39:954-960.
40. Gowen M: Interleuken 1 and tumor necrosis factor. In Cytokines and Bone. Boca Raton, Florida: CRC Press; 1992:71-91.
41. Garrett IR, Mundy GR: Relationship between interleukln-1 and prostaglandins in resorbing neonatal calvariae. J Bone Miner Res 1989, 4:789-794.
42. Pfeilschifter J, Seyedin SM, Mundy GR: Transforming growth factor β inhibits bone resorption in fetal rat long bone cultures. J Clin Invest 1988, 82:680-685.
43. Gowen M, Mundy GR: Actions of recombinant interleukin-1, interleukin-2 and interferon gamma on bone resorption in vitro. J Immunol 1986, 136:2478-2482.
44. Gowen M: Cytokines and Bone. Bocca Rotan, Florida: CRC Press; 1992.
45. Catherwood BD, Friedler RM, Singer FR, et al.: Sites of clearance of endogenous parathyroid hormone in the vitamin D deficient dog. Endocrinology 1976, 98:228-236.
46. Zull JE, Chuang J: Characterization of parathyroid formone fragments produced by cathepsin D. J Biol Chem 1985, 260:1608-1613.
47. Hamdy NAT, Kanis JA, Beneton MNC, et al.: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 1995, 310:358-363.
48. Salusky IB, Ramirez JA, Oppenheim W, et al.: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994, 45:253-258.
49. Salusky IB, Coburn JW, Brill J, et al.: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988, 33:975-982.
50. Meema HE, Rabinovich S, Meema S: Improves radiological diagnosis of azotemic osteodystrophy. Radiology 1972, 102:1-10.
51. Ott SM, Maloney NA, Coburn JW, et al.: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 1982, 307:709-713.
52. Pierides AM, Edwards WG Jr, Cullu US Jr, et al.: Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980, 18:115-124.
53. Sherrard DJ, Ott SM, Maloney NA, Andress DL, Coburn JW: Uremic osteodystrophy: Classification, cause and treatment. In Clinical Disorders of Bone and Mineral Metabolism. Edited by B Frame, J Potts. Amsterdam: Excerpta Medica; 1984:254-259.
54. Hernandez D, Concepcion MT, Lorenzo V, et al.: Adynamic bone disease with negative aluminum staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994, 9:517-523.
55. Sherrard D, Hercz G, Pei Y, et al.: The spectrum of bone disease in end-stage renal failure: An evolving disorder. Kidney Int 1993, 43:436-442.
56. Goodman WG, Ramirez JA, Belin TR, et al.: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994, 46:1160-1166.
57. Hercz G, Pei Y, Greenwood C, et al.: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 1993, 44:860-866.
58. Sanchez CP, Goodman WG, Ramirez JA, et al.: Calcium-regulated parathyroid hormone secretion in adynamic renal osteodystrophy. Kidney Int 1995, 48:838-843.
59. Osorio A, Seidel FG, Warady BA: Hypercalcemia and pancreatitis in a child with adynamic bone disease. Pediatr Nephrol 1997, 11:223-225.
60. Chantler C, Donckerwolcke RA, Brunner FP, et al.: Combined report on regular dialysis and transplantation of children in Europe. Proc EDTA 1977, 14:70-112.
61. Chesney RW, Moorthy AV, Eisman JA, et al.: Increased growth after long-term oral 1,25-vitamin D in childhood renal osteodystrophy. N Engl J Med 1978, 298:238-242.
62. Blum WF, Ranke M, Kietzmann K, et al.: Excess IGF-binding proteins in chronic renal failure: Evidence for relative GH resistance and inhibition of somatomedin activity. Proceedings of the Workshop on IGF Binding Proteins. Amsterdam: Elsevier; 1990:25-30.
63. Salusky IB, Brill J, Oppenheim W, et al.: Features of renal osteodystrophy in pediatric patients receiving regualr peritoneal dialysis. Semin Nephrol I 1989, 9:37-42.
64. Mehls O: Renal osteodystrophy in children: Etiology and clinical aspects. In End Stage Renal Disease in Children. Edited by RN Fine, AB Gruskin. Philadelphia: WB Saunders; 1984:227-250.
65. Loder RT, Hensinger RN: Slipped capital femoral epiphysis associated with renal failure osteodystrphy. J Pediatr Orthoped 1997, 17:205-211.
66. Henderson RG, Russel RGG, Ledingham JG: Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 1974, 249:379-384.
67. Gipstein RM, Coburn JW, Adams JA, et al.: Calciphylaxis in man: A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 1976, 136:1273-1280.
68. Maschio G, Oldrizzi L, Tessitore N, et al.: Effects of dietary and protein restriction on the progression of early renal failure. Kidney Int 1982, 22:371-376.
69. Andreoli SP, Bergstein JM, Sherrard DJ: Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984, 310:1079-1084.
70. Sedman AB, Miller NL, Warady BA, et al.: Aluminum loading in children with chronic renal failure. Kidney Int 1984, 26:201-204.
71. Bakir AA, Hryhorczuk DO, Berman E, et al.: Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Organs 1986, 32:171-176.
72. Salusky IB, Coburn JW, Foley J, et al.: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-cintaining gels in children receiving dialysis. J Pediatr 1986, 108:767-770.
73. Schiller LR, Santa Ana CA, Sheikh MS, et al.: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989, 320:1110-1113.
74. Wallot M, Bonzel K-E, Winter A, et al.: Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 1996, 10:625-630.
75. Slatopolsky E, Weerts C, Norwood K, et al.: Long-term effects of calcium carbonate and 2.5 mEq/L calcium dlalysate on mineral metabolism. Kidney Int 1989, 36:897-903.
76. Baker LR, Abrams L, Roe CJ, et al.: 1,25[OH]2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 1989, 35:661-669.
77. Slatopolsky E, Weerts C, Thielan J, et al.: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984, 74:2136-2143.
78. Silver J, Naveh-Many T, Mayer H, et al.: Regualtion by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986, 78:1296-1301.
79. Shimada H, Nakamura M, Marumo F: Influence of aluminum on the effect of 1-alpha-(OH)D3 on renal osteodystrophy. Nephron 1983, 35:163-170.
80. Kanis JA, Henderson RG, Heynen G, et al.: Renal osteodystrophy in nondialyzed adolescents: Long-term treatment of 1α-hydroxycholecalciferol. Arch Dis Child 1977, 52:473-481.
81. Teitelbaum SL, Bone JM, Stein PM: Califediol in chronic renal insufficiency: Skeletal response. JAMA 1976, 235:164-167.
82. Brown AJ, Ritter CR, Finch JL, et al.: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989, 84:728-732.